3'-Deoxy-3'-18F-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients

There is no fulltext present in this item.

Title:	3'-Deoxy-3'-18F-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients
Author(s):	Idema, A.J.S. ; Hoffmann, A.L.; Boogaarts, H.D. ; Troost, E.G.C. ; Wesseling, P. ; Heerschap, A. ; van der Graaf, W.T. ; Grotenhuis, J.A. ; Oyen, W.J.G.
Publication year:	2012
Source:	The Journal of Nuclear Medicine (1978), vol. 53, iss. 12, (2012), pp. 1904-1910
ISSN:	0161-5505
DOI:	https://doi.org/10.2967/jnumed.112.105544
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/108702
Display more details
Subject:	NCEBP 2: Evaluation of complex medical interventions NCEBP 2: Evaluation of complex medical interventions ONCOL 5: Aetiology, screening and detection ONCOL 2: Age-related aspects of cancer NCEBP 4: Quality of hospital and integrated care ONCOL 3: Translational research ONCOL 3: Translational research N4i 1: Pathogenesis and modulation of inflammation ONCOL 3: Translational research NCMLS 3: Tissue engineering and pathology ONCOL 3: Translational research NCMLS 4: Energy and redox metabolism ONCOL 3: Translational research NCMLS 3: Tissue engineering and pathology
Organization:	Neurosurgery Radiation Oncology Pathology Radiology Medical Oncology Nuclear Medicine
Journal title:	The Journal of Nuclear Medicine (1978)
Volume:	vol. 53
Issue:	iss. 12
Page start:	p. 1904
Page end:	p. 1910
Abstract:	3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) is a radiopharmaceutical depicting tumor cell proliferation with PET. In malignancies of the lung, breast, head and neck, digestive tract, brain, and other organs, quantitative assessment of (18)F-FLT targeting has been shown to correlate with the proliferation marker Ki-67 and with clinical outcome measures such as time to progression and overall survival (OS). The aim of this study was to assess various PET segmentation methods to estimate the proliferative volume (PV) and their prognostic value for OS in patients with suspected high-grade glioma. METHODS: Twenty-six consecutive patients underwent preoperative (18)F-FLT PET/CT and T1-weighted MRI of the brain after contrast application. The maximum standardized uptake value (SUV(max)) of all tumors was calculated, and 3 different segmentation methods for estimating the PV were used: the 50% isocontour of the SUV(max) signal for the PV(50%), the signal-to-background ratio (SBR) for an adaptive threshold delineation (PV(SBR)) method, and the iterative background-subtracted relative threshold level (RTL) method to estimate the PV(RTL). The prognostic value of the SUV(max) and the different PVs for OS were assessed. RESULTS: Twenty-two patients had glioblastoma multiforme, 2 had anaplastic oligodendroglioma, 1 had anaplastic ependymoma, and 1 had anaplastic astrocytoma. The median OS was 397 d (95% confidence interval, 204-577); 19 patients died during the follow-up period. The PV(SBR) showed a significantly (P = 0.002) better association with OS than did SUV(max), PV(RTL), and PV(50%). Receiver-operating-characteristic analysis resulted in a threshold volume for the PV(SBR) of 11.4 cm(3), with a sensitivity and specificity of 70% and 83%, respectively, for the prediction of OS. Kaplan-Meier analyses showed a significant discrimination between short and long OS (P = 0.024, log rank) for this threshold. CONCLUSION: The PV as determined by (18)F-FLT PET is associated with OS in high-grade malignant gliomas. The SBR method yielded the best results to predict short and long OS.